521,327 Shares in Immunocore Holdings PLC Sponsored ADR $IMCR Acquired by Braidwell LP

Braidwell LP bought a new stake in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 521,327 shares of the company’s stock, valued at approximately $16,552,000.

A number of other hedge funds also recently modified their holdings of the business. Harbour Investments Inc. boosted its position in shares of Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after buying an additional 388 shares during the period. Leonteq Securities AG acquired a new stake in Immunocore during the 4th quarter worth about $30,000. Orion Porfolio Solutions LLC grew its stake in Immunocore by 4.5% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock valued at $752,000 after acquiring an additional 1,031 shares in the last quarter. Arax Advisory Partners increased its holdings in shares of Immunocore by 302.9% in the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after purchasing an additional 1,042 shares during the period. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of Immunocore by 2.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,324 shares of the company’s stock worth $1,534,000 after purchasing an additional 1,197 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on IMCR shares. TD Cowen raised shares of Immunocore to a “strong-buy” rating in a research report on Monday, August 24th. Mizuho increased their target price on shares of Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. Finally, Zacks Research raised shares of Immunocore from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Immunocore has a consensus rating of “Moderate Buy” and an average price target of $56.38.

Immunocore Trading Up 1.4%

NASDAQ:IMCR opened at $37.37 on Thursday. The company has a market capitalization of $1.92 billion, a P/E ratio of -101.00 and a beta of 0.74. The stock’s 50 day moving average price is $34.25 and its 200 day moving average price is $31.68. The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.44 and a current ratio of 4.47. Immunocore Holdings PLC Sponsored ADR has a 52 week low of $27.56 and a 52 week high of $40.71.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Friday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%. On average, research analysts forecast that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current fiscal year.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.